On April 14, 2020, Shijiazhuang Yiling Pharmaceutical Co., Ltd. issued a notice saying that Shijiazhuang Yiling Pharmaceutical Co., Ltd. and its subsidiary company Beijing Yiling Pharmaceutical Co., Ltd. have received the Letter of Approval of Supplementary Application issued by the National Medical Products Administration for the new indication extension application for Lianhua Qingwen Capsules and Lianhua Qingwen Granules. It is approved that "It can be used for the treatment of fever, cough and weakness caused by mild to moderate cases during the routine treatment of COVID-2019" in the "Functions and Indications" in addition to the other already authorized indications of Lianhua Qingwen Capsules and Lianhua Qingwen Granules. Among others, the sentence "The course of treatment is 7 to 10 days for the mild to moderate cases of COVID-2019." is also added in the " Administration and Dosage" section.
Recently, Shijiazhuang Yiling Pharmaceutical Co., Ltd. received the marketing authorization for modern botanic drug issued by the Ministry of Health of Thailand, which approves the registration of Lianhua Qingwen Capsules of the company as a kind of modern botanic drug in Thailand. The relevant information is notified as described below.
Il 12 marzo un gruppo di esperti composto da 9 membri, formato in manieracongiunta dalla Commissione Sanitaria Nazionale cinese e dalla Croce rossa cinese, èstato inviato dalle autorità cinesi, trasportando da Shanghai a Roma 100.000scatole di capsule di Lianhua Qingwen, cure mediche divario genere e fornituredi genere protettivo. Questo gesto è stato perpetrato per supportare laprevenzione e il controllo della epidemia di corona virus in Italia. Questa èla terza squadra di esperti virologi inviata dalla Cina dopo aver sostenutol'Iran e l'Iraq.
Yiling Pharmaceutical Company dares to hand over the drugs that are considered good on the market to our clinicians for a strict evidence-based medicine experiment to see if they work.
Zhong Nanshan at Press Conference of Guangdong Government